Self-Regulating CAR-T Cells Modulate Cytokine Release Syndrome in Adoptive T Cell Therapy

With a humanized NSG-SGM3 mouse model, investigators showed reduced CRS-related toxicity in mice treated with CAR-T cells secreting tocilizumab-derived single-chain variable fragment, yielding a safety profile superior to that of single-dose systemic tocilizumab administration.